The 7th World Hypertension Congress together with the 21st Arterial Hypertension Congress of SBC/DHA, scheduled on May 13–15, 2027 in Goiania, Brazil, is one of the leading global forums for sharing with national and international experts recent findings in the cardiovascular and hypertension field.
Submission of Abstracts offers an opportunity to share fresh science results, engage in qualified scientific discussions, and increase the global visibility of the work presented.
| Stage | Period |
|---|---|
| Submission of abstracts (Stages 1 to 5) | 05 October until 30 November 2026 |
| Review of abstracts – Abstracts Review Committee (ARC) | January 2027 |
| Release of results / Presentation format | January/February 2027 |
| Confirmation of presentation and submission of the e-poster | February to April 2027 |
Submission of abstracts is free of charge.
Presenting authors of approved abstracts must be registered for the Congress.
Each approved Abstract grants a 50% discount on one registration for one of the registered authors.
The discount is individual, non-transferable, non-cumulative, and calculated based on the pricing tier in effect at the time of registration.
There will be no refunds for registrations already completed.
Submission of an abstract implies the authors’ formal commitment to register for and present the work in person in Goiania, if approved.
For an approved and confirmed abstract: failure to submit the material and/or failure to register for the Congress by 29th April will result in the abstract being withdrawn from the scientific program and from all event publications.
All abstracts must be submitted in English.
The review process is blind; therefore, the text must not contain information that allows identification of the authors or institutions, under penalty of disqualification.
Abstracts must not include commercial drug names.
Abstracts that directly or indirectly identify patients will be disqualified.
Abstracts that have already been presented, awarded, or published at the time of submission may be disqualified and will not be eligible for awards.
The authors responsible for the submission declare, for all purposes, that they are aware of and have fully complied with the ethical requirements applicable to the study presented.
They further declare that supporting documentation is available and can be sent to the Scientific Committee on request, with the authors bearing sole responsibility for any incorrect information or omissions related to ethical compliance.
Results must be clear, and conclusions must be based on the data presented.
Non-original work, such as narrative reviews, will not be accepted, but systematic reviews/meta-analyses may be submitted, provided the methodology is described.
Abstracts using PRISMA or QUOROM methodology will be accepted for peer review evaluation.
The Scientific Committee may decline to accept for presentation abstracts that are exclusively descriptive and based on secondary administrative data, such as DATASUS, when there is no well-defined research question, no statistical analysis consistent with the stated objectives, or no relevant scientific contribution.
Studies of this type are expected to present a consistent analytical approach, appropriate context for the results, and a critical discussion of the limitations inherent to the database used.
For the Young Researcher category, the abstract’s coordinator/advisor must be included as the last author and must hold an active registration with the relevant professional board.
At the time of submission, the author must declare whether generative Artificial Intelligence tools were used.
This disclosure is declaratory in nature and aims to ensure transparency in the scientific process.
The declaration options range from no use of AI to more extensive use throughout the development of the text.
Regardless of the level of use, full responsibility for the scientific content, its originality, accuracy, critical review, and ethical compliance remains exclusively with the authors.
Complete the full registration with name, email, national ID/tax ID, phone number, date of birth, and other details.
All communication will be conducted through the email address and phone numbers registered at this stage.
Original Research: Unpublished scientific work with a well-defined research question, based on an appropriate scientific method. Includes observational or experimental studies, clinical trials, translational research, meta-analyses, or systematic reviews, structured with an introduction, objectives, methods, results, and conclusions.
Case Report / Clinical Cases: Detailed description of one or more clinical cases of scientific or educational relevance, involving rare conditions, atypical presentations, diagnostic or therapeutic challenges, or innovative approaches, accompanied by a discussion grounded in the literature.
Abstracts from the Pharmaceutical Industry must be disclosed in the corresponding sponsorship field and will not be eligible for awards.
If approved, they must state in the e-poster header that the work is sponsored, including the name/logo of the company involved.
Young Researcher: undergraduate research students, medical researchers, or related fields up to 35 (thirty-five) years of age on the date of submission, and/or anyone enrolled in a residency or graduate program who does not fit the other category.
Researcher: other researchers who do not fit the other category.
For the Young Researcher category, the advisor must be included as the last author.
Maximum number of authors: 12
Maximum number of institutions: 12
The abstract should preferably be presented by the first author, but may be presented by a co-author who meets the category criteria.
Title (up to 250 characters); Introduction/Background; Objectives; Methods; Results and Conclusions; Up to 3 keywords.
Title (up to 250 characters); Introduction; Case Description; Conclusions; Up to 3 keywords.
The system allows text to be pasted directly from editors such as Word.
The total abstract text must be between 1,000 and 2,500 characters, including spaces.
Content exceeding the established limits will be automatically disregarded.
Up to 2 images are allowed (JPG, JPEG, or PNG formats).
Minimum dimensions of 500px and maximum of 1080px.
Text entered is saved as each stage is completed and may be edited until the deadline while in draft form.
After that date, no changes will be allowed. You must click Submit to finalize the submission.
Check that all stages are complete, as well as the authorship and author details, since it will not be possible to make changes after the submission deadline.
Abstracts will be reviewed blindly by the Abstracts Review Committee (ARC), by up to five different reviewers.
The highest and lowest scores will be discarded, and the arithmetic mean of the remaining scores will be considered.
The number of abstracts approved for presentation will depend on the quantity and quality of the abstracts submitted, as well as the availability of time and space at the Congress.
The approved abstract should preferably be presented by the first author, but may be presented by a co-author who meets the category criteria.
The name of the presenter must be provided to the organization by 29th April, 2027.
All presentations and materials must be delivered in English.
Abstracts selected for oral presentation will have a total duration of 12 minutes, with:
As this is an international event, presentations and slides must be in English.
All other approved abstracts, whether Original Research or Case Reports, will be presented in e-poster format, with content required to be in English.
Judging will take place live, during the event’s breaks, at specific times by category or area, to be announced later.
Each presentation will last a total of 10 minutes, with 7 minutes for presentation and 3 minutes for interaction with discussants.
The submission of the e-poster is mandatory by 29th April, through the link: https://XXXXXXXXXXXXXXXXX
In-person judging will be carried out by review panels made up of up to three judges, who will determine the winners based exclusively on presentation performance, disregarding scores from previous phases.
The final average will not be disclosed, and decisions are final.
The winners of the “Best Abstracts” award will be announced during the Congress, with the awards presented at the closing ceremony, attendance of the competing authors being mandatory; detailed information about the awards will be published later on the official website.
Approved abstracts will be published in an electronic supplement of the Arquivos Brasileiros de Cardiologia (ABC Cardiol) and the Journal of Human Hypertension.
Authors of abstracts selected for oral presentation are invited to submit the full manuscript through the fast-track process to Journal of Human Hypertension and ABC Cardiol.
If accepted following peer review, the article will be published in the journal.
Certificates will be made available exclusively for abstracts actually presented at the Congress.
Two certificates will be issued: one in the name of the author presenting the abstract, and another in the name of the abstract, listing the names of all its authors.
Under Carta Circular No. 166/2018 – CONEP/SECNS/MS, every case report must be submitted to a Research Ethics Committee.
There is no limit on the number of abstracts per author.
Two certificates will be issued: one in the name of the author presenting the abstract, and another in the name of the abstract, listing the names of all its authors.
For the Young Researcher category, the abstract’s coordinator/advisor must be included as the last author and must hold an active registration with the relevant professional board.
Guidelines for Submission of Abstracts
